Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Brian R. Champion"'
Autor:
Olmo Sonzogni, Daniel E. Zak, Maria Stella Sasso, Rochelle Lear, Alice Muntzer, Manuela Zonca, Katy West, Brian R. Champion, James B. Rottman
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Although chimeric antigen receptor (CAR) T cells have emerged as highly effective treatments for patients with hematologic malignancies, similar efficacy has not been achieved in the context of solid tumors. There are several reasons for this dispari
Externí odkaz:
https://doaj.org/article/fc074a31364141db8230cf60b8ebcac2
Autor:
Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour, Margaret R. Duffy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-18 (2019)
Abstract Background Tumour-associated macrophages (TAMs) are often implicated in cancer progression but can also exert anti-tumour activities. Selective eradication of cancer-promoting (M2-like) TAM subsets is a highly sought-after goal. Here, we hav
Externí odkaz:
https://doaj.org/article/d5fee97270fd469da9e2aa78cc47e661
Autor:
Kerry D. Fisher, Leonard W. Seymour, Brian R. Champion, Paul Miller, Adam Lambert, Clare Verrill, Richard J. Bryant, Leticia Campo, Joachim Hagel, Eleanor M. Scott, Alice Muntzer, Janet Lei-Rossmann, Margaret R. Duffy, Joshua D. Freedman
Supplementary Files detailing additional experiments supporting the conclusions of the manuscript, including additional activation, cytotoxicity, and cytokine analyses. Supplementary tables contain more details on characterisation of patient biopsies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::485e705c7efbfb716257f1d09ff10e04
https://doi.org/10.1158/0008-5472.22419483
https://doi.org/10.1158/0008-5472.22419483
Autor:
Kerry D. Fisher, Leonard W. Seymour, Brian R. Champion, Paul Miller, Adam Lambert, Clare Verrill, Richard J. Bryant, Leticia Campo, Joachim Hagel, Eleanor M. Scott, Alice Muntzer, Janet Lei-Rossmann, Margaret R. Duffy, Joshua D. Freedman
Time-lapse sequence of uninfected control cultures of DLD, NHDF, and T cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2faf0839ee83d77b36795cc68ec037f
https://doi.org/10.1158/0008-5472.22419492.v1
https://doi.org/10.1158/0008-5472.22419492.v1
Autor:
Kerry D. Fisher, Leonard W. Seymour, Brian R. Champion, Paul Miller, Adam Lambert, Clare Verrill, Richard J. Bryant, Leticia Campo, Joachim Hagel, Eleanor M. Scott, Alice Muntzer, Janet Lei-Rossmann, Margaret R. Duffy, Joshua D. Freedman
Effective immunotherapy of stromal-rich tumors requires simultaneous targeting of cancer cells and immunosuppressive elements of the microenvironment. Here, we modified the oncolytic group B adenovirus enadenotucirev to express a stroma-targeted bisp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c1027b95bdb83ff43117766fe19c258
https://doi.org/10.1158/0008-5472.c.6510393.v1
https://doi.org/10.1158/0008-5472.c.6510393.v1
Autor:
Maria Stella Sasso, Rachel Bergin, Rochelle Lear, Darren Plumb, Manuela Zonca, Eva Vainiute, Meg Snowden, Tae Hyun Jang, Alice Muntzer, Carla C. Cerqueira, Katy West, Samantha Bucktrout, Brian R. Champion
Publikováno v:
Cancer Research. 83:5746-5746
Efficacy of Chimeric Antigen Receptor (CAR) T cell therapy against solid tumors is hampered by multiple barriers, including tumor-associated immunosuppression, poor CAR-T cell trafficking into solid tumor masses and shortage of highly expressed cance
Autor:
Christine Wilkinson-Blanc, Ramon Salazar, Ignacio Duran, Kerry D. Fisher, Simon Alvis, Karen Geboes, Emiliano Calvo, Hilary McElwaine-Johnn, Sylvie Rottey, Gillian Pover, John William Beadle, Brian R. Champion, Luc Dirix, Jean-Pascal Machiels
Publikováno v:
Journal for Immunotherapy of Cancer
Digital.CSIC. Repositorio Institucional del CSIC
instname
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Dipòsit Digital de la UB
Universidad de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
instname
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Dipòsit Digital de la UB
Universidad de Barcelona
[Background] Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2033338b56bbb71a2a23187410b024d0
https://ora.ox.ac.uk/objects/uuid:a376bcd1-88f4-4b2a-81fc-e95acfcb3230
https://ora.ox.ac.uk/objects/uuid:a376bcd1-88f4-4b2a-81fc-e95acfcb3230
Autor:
Egon J. Jacobus, William K. Taverner, Arthur Dyer, Tzveta D. Pokrovska, Kerry D. Fisher, Janet Lei-Rossmann, Katharine J. Herbert, Richard Baugh, Geoff S. Higgins, Gonzalo Rodriguez-Berriguete, Rathi Puliyadi, Remko Prevo, Brian R. Champion, Len Seymour, Giovanna Granata, Sally Frost
Publikováno v:
Cancers
Volume 12
Issue 4
Cancers, Vol 12, Iss 4, p 798 (2020)
Volume 12
Issue 4
Cancers, Vol 12, Iss 4, p 798 (2020)
Ionising radiation causes cell death through the induction of DNA damage, particularly double-stranded DNA (dsDNA) breaks. Evidence suggests that adenoviruses inhibit proteins involved in the DNA damage response (DDR) to prevent recognition of double
Autor:
Kerry D. Fisher, Sally Frost, Hena Khalique, Brian R. Champion, Egon J. Jacobus, Joshua D Freedman, Arthur Dyer, Margaret R. Duffy, Brian Lyons, Alison Carr, Leonard W. Seymour, William K. Taverner, Eleanor M. Scott
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-18 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-18 (2019)
Background Tumour-associated macrophages (TAMs) are often implicated in cancer progression but can also exert anti-tumour activities. Selective eradication of cancer-promoting (M2-like) TAM subsets is a highly sought-after goal. Here, we have devised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3205af0bae0b08530ab9e98cb1aae791
https://doi.org/10.1186/s40425-019-0807-6
https://doi.org/10.1186/s40425-019-0807-6
Autor:
Margaret R. Duffy, Len Seymour, Lorna Slater, Janet Lei, Silvio Hemmi, Brian R. Champion, Katy West, Fred Lilley, Kerry D. Fisher, Alice Brown, Egon J. Jacobus, William K. Taverner
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-16 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-16 (2018)
Background Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytotoxicity to cancer cells with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da7a5e7b3014a547ffe74b61fdbadf01
https://doi.org/10.1186/s40425-018-0350-x
https://doi.org/10.1186/s40425-018-0350-x